Humanin is a 24-amino acid peptide encoded within the mitochondrial genome — one of only a small number of known mitochondrial-derived peptides (MDPs). First identified in 2001 from a cDNA library screen of surviving neurons in Alzheimer’s disease brain tissue, humanin was notable as the first open reading frame within mitochondrial 16S rRNA shown to produce a functional peptide with cytoprotective properties.[1][2]

Research interest in the humanin peptide has grown substantially since its discovery, with preclinical studies investigating its roles in neuroprotection, metabolic regulation, cellular stress resistance, and aging biology. Humanin circulates endogenously in human plasma, and levels appear to decline with age — a pattern that has driven investigation into its potential relevance to age-related pathology.[3]

Compound Profile

What Does Humanin Actually Do?

Humanin research suggests it functions as a broad-spectrum cytoprotective peptide. In preclinical models, it has demonstrated the ability to protect cells from apoptosis triggered by diverse insults including amyloid-beta toxicity, oxidative stress, serum deprivation, and ischemia-reperfusion injury.[1][4] The scope of its protective effects across multiple tissues and stress types is unusual for a peptide of its size.

Circulating humanin levels in humans have been correlated inversely with age and positively with mitochondrial function markers. Centenarian populations and their offspring tend to show higher circulating humanin levels compared to age-matched controls, though whether this reflects cause or consequence of longevity remains unclear.[3]

How Humanin Works

Humanin appears to exert cytoprotection through multiple receptor-mediated and intracellular signalling pathways. Extracellularly, humanin binds the formyl peptide receptor-like 1 (FPRL1/FPR2), a G protein-coupled receptor expressed in neurons and immune cells. Structural studies have revealed the molecular basis of this interaction, showing humanin competes with amyloid-beta for FPR2 binding.[5]

Intracellularly, humanin interacts directly with pro-apoptotic proteins including Bax and BID, preventing their translocation to the mitochondrial membrane and thereby inhibiting the intrinsic apoptosis cascade. Humanin also binds IGFBP-3, modulating IGF-1 signalling and influencing metabolic pathways involved in glucose homeostasis and insulin sensitivity.[3]

The STAT3 signalling axis appears to mediate many of humanin’s downstream effects. Humanin activates STAT3 phosphorylation through a trimeric receptor complex composed of CNTFR, WSX-1, and gp130, linking mitochondrial peptide signalling to classical cytokine receptor pathways.

Longevity / Healthy Aging Context

Humanin’s position as a mitochondrial-derived peptide that declines with age has made it a focus of longevity and healthy aging research. The observation that centenarians maintain higher circulating humanin levels has generated hypotheses about its role as an endogenous protective signal against age-related cellular decline.[3]

Preclinical aging models have shown that humanin administration can attenuate markers of cellular senescence and oxidative damage. In rodent studies, humanin treatment improved mitochondrial function in aged tissues and reduced age-associated inflammation. These effects appear consistent with humanin’s role as a retrograde signalling molecule from mitochondria to the nucleus.[4]

However, the causal relationship between humanin levels and aging outcomes remains unestablished in humans. While correlational data from centenarian studies is suggestive, interventional clinical trials have not yet been conducted. The evidence confidence for longevity applications remains preclinical. Compare with Epithalon and MOTS-c for related longevity-focused peptide profiles, or see the broader Longevity / Healthy Aging goal page.

Recovery & Sleep Context

Humanin’s cytoprotective effects extend to tissue recovery contexts, with preclinical evidence suggesting it may support cellular resilience under stress conditions relevant to recovery and sleep research. Its anti-apoptotic mechanism — blocking Bax translocation and caspase activation — is relevant to tissue repair processes where programmed cell death can impair recovery.[4]

In cardiac ischemia-reperfusion models, humanin pretreatment reduced infarct size and preserved cardiomyocyte viability, suggesting a role in tissue protection during recovery from ischaemic insults.[6] Similar protective effects have been observed in renal and hepatic injury models, indicating broad tissue applicability.

Research into humanin’s effects on sleep architecture or circadian biology is limited. The recovery context is primarily derived from tissue-level cytoprotection data rather than systemic recovery or sleep quality endpoints. See the Recovery & Sleep goal page for broader context.

Muscle Growth Context

Recent research has identified humanin as a potential modulator of skeletal muscle homeostasis, relevant to muscle growth research contexts. In vitro studies using human skeletal muscle cells have demonstrated that humanin attenuates dexamethasone-induced muscle atrophy, suggesting a role in protecting muscle tissue from glucocorticoid-mediated wasting.[7]

The mechanism appears to involve humanin’s interaction with IGFBP-3 and downstream IGF-1 signalling pathways. By binding IGFBP-3, humanin may increase local IGF-1 bioavailability — a pathway with established relevance to muscle protein synthesis and hypertrophy signalling.[3] This connects humanin to broader anabolic signalling networks studied in peptides like IGF-1 LR3.

However, direct evidence for humanin-mediated muscle hypertrophy in vivo is absent. The current evidence supports an anti-catabolic rather than anabolic role, with the most robust data coming from muscle-wasting prevention models rather than growth promotion paradigms. See the Muscle Growth goal page for related research.

Humanin Benefits

• Broad cytoprotection: Research demonstrates protective effects against apoptosis across neuronal, cardiac, pancreatic, and skeletal muscle cell types — an unusually wide tissue spectrum for a single peptide.[1][4]
• Neuroprotective activity: Originally discovered for protection against amyloid-beta toxicity, humanin has shown neuroprotective effects in multiple neurodegenerative disease models including Alzheimer’s-relevant insults.[1][2][5]
• Metabolic regulation: Preclinical data suggests humanin improves insulin sensitivity and glucose homeostasis through IGFBP-3/IGF-1 axis modulation.[3]
• Anti-inflammatory properties: Humanin reduces inflammatory signalling in multiple tissue contexts, potentially through FPRL1/FPR2-mediated immune modulation.[5]
• Mitochondrial function support: As an endogenous mitochondrial peptide, humanin appears to participate in retrograde mitochondria-to-nucleus signalling that maintains cellular bioenergetic capacity.[8]

Humanin Side Effects

Humanin is an endogenous peptide — produced naturally by human mitochondria — which provides a theoretical safety advantage over synthetic compounds. Preclinical toxicology data across multiple animal studies has not identified significant adverse effects at physiologically relevant concentrations.[4]

Potential considerations from preclinical research include:

• Anti-apoptotic concerns: Humanin’s potent inhibition of programmed cell death raises theoretical questions about effects on normal cellular turnover and tumour surveillance, though no pro-tumorigenic effects have been reported in animal studies.
• Dose-response complexity: Some studies suggest biphasic or non-linear dose-response relationships, where supraphysiological concentrations may not maintain the same effect profile as lower levels.
• Limited human safety data: No formal clinical trials have assessed humanin safety in humans. All safety inferences are derived from preclinical models and observational data on endogenous levels.

Half-Life

Endogenous humanin has a relatively short circulating half-life, estimated at minutes to a few hours in preclinical models. This short duration has driven development of analogue peptides with enhanced stability, most notably [Gly14]-humanin (HNG), which incorporates a single amino acid substitution that increases potency approximately 1,000-fold while extending biological activity.[3]

The pharmacokinetic profile of exogenous humanin has been characterised primarily in rodent models, where intraperitoneal and subcutaneous administration routes have been used. Tissue distribution studies indicate humanin accumulates preferentially in metabolically active organs including brain, heart, and liver.

Limits of Current Evidence

• No human clinical trials: Despite over two decades of research since discovery, humanin has not entered formal clinical development. All efficacy data derives from cell culture and animal models.
• Correlational longevity data: The centenarian humanin level observations are associative, not causal. Higher humanin could be a marker rather than a driver of longevity.
• Analogue complexity: Much of the preclinical literature uses HNG or other analogues rather than native humanin, complicating direct translation.
• Measurement variability: Circulating humanin assays have faced standardisation challenges, with different ELISA platforms yielding variable absolute concentrations.
• Publication bias: As a peptide with an appealing narrative (mitochondrial origin, longevity connection), positive results may be disproportionately published.

Verdict

Humanin is a genuinely novel class of signalling molecule — an endogenous mitochondrial-derived peptide with demonstrated cytoprotective properties across multiple tissue types and stress models. The breadth of preclinical evidence is substantial, and the centenarian correlation data adds biological plausibility to longevity-related hypotheses.

However, the complete absence of human interventional data after 25 years of research is notable. Humanin remains firmly in the preclinical research phase. The evidence supports it as a biologically significant endogenous peptide with therapeutic potential, but translational confidence should remain proportional to the available data — which is extensive in rodents and absent in human trials.

FAQ

What is humanin peptide?

Humanin is a 24-amino acid peptide encoded within the mitochondrial genome. It was discovered in 2001 from surviving neurons in Alzheimer’s disease brain tissue and is classified as a mitochondrial-derived peptide (MDP). Research suggests it functions as a cytoprotective signalling molecule with effects across multiple tissues.

Is humanin the same as MOTS-c?

No. Both humanin and MOTS-c are mitochondrial-derived peptides, but they are encoded by different regions of mitochondrial DNA and have distinct mechanisms. Humanin is primarily studied for cytoprotection and neuroprotection, while MOTS-c research focuses on metabolic regulation and exercise biology.

Why do humanin levels decline with age?

Circulating humanin levels decrease with age, likely reflecting age-related decline in mitochondrial function and mitochondrial DNA copy number. Since humanin is encoded by mitochondrial DNA, reduced mitochondrial biogenesis and increased mitochondrial damage with aging would be expected to reduce humanin production.

What is HNG humanin?

[Gly14]-humanin (HNG) is a synthetic analogue of humanin in which the serine at position 14 is replaced with glycine. This single substitution increases biological potency approximately 1,000-fold compared to native humanin, making HNG the most commonly used humanin variant in preclinical research.

What does humanin research suggest about longevity?

Observational studies have found that centenarians and their offspring tend to have higher circulating humanin levels than age-matched controls. Preclinical studies show humanin can reduce age-related cellular damage markers. However, whether humanin causally influences lifespan or is simply a biomarker of healthy aging remains unestablished.

Has humanin been tested in clinical trials?

As of current evidence, humanin has not entered formal human clinical trials for any therapeutic indication. All efficacy and safety data derives from preclinical models (cell culture and animal studies). The peptide remains in the research phase with no approved clinical applications.

References

1. Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proc Natl Acad Sci U S A. 2001. PMID: 11371646
2. Hashimoto Y, et al. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer’s disease-relevant insults. J Neurosci. 2001. PMID: 11717357
3. Hazafa A, et al. Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases. Life Sci. 2021. PMID: 33130077
4. Zhu S, et al. The Molecular Structure and Role of Humanin in Neural and Skeletal Diseases, and in Tissue Regeneration. Front Cell Dev Biol. 2022. PMID: 35372353
5. Zhu Y, et al. Structural basis of FPR2 in recognition of Aβ42 and neuroprotection by humanin. Nat Commun. 2022. PMID: 35365641
6. Kumfu S, et al. Humanin Exerts Neuroprotection During Cardiac Ischemia-Reperfusion Injury. J Alzheimers Dis. 2018. PMID: 29376862
7. Elhusseiny R, et al. Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells. Physiol Rep. 2026. PMID: 41732124
8. Karachaliou CE, et al. Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives. Biology (Basel). 2023. PMID: 38132360

SS-31 is a water-soluble, cell-permeable tetrapeptide with the sequence D-Arg–2′,6′-dimethyltyrosine (Dmt)–Lys–Phe–NH₂. It belongs to the Szeto-Schiller peptide family — a series of aromatic-cationic peptides designed to accumulate selectively within mitochondria. The alternating aromatic and cationic residues in its structure enable rapid, energy-independent uptake across cell membranes, concentrating the peptide over 1,000-fold within mitochondria within minutes of exposure.

Unlike triphenylphosphonium (TPP⁺)-conjugated molecules that rely on mitochondrial membrane potential for uptake, SS-31 accumulates in the inner mitochondrial membrane independently of membrane potential. This makes it effective even in dysfunctional mitochondria where the electrochemical gradient is compromised — a critical advantage in disease states and ageing.

The compound was originally designated as a mitochondrial-targeted antioxidant, but subsequent research has revealed that its primary mechanism involves direct interaction with cardiolipin rather than free radical scavenging. This distinction is significant: while general antioxidants reduce oxidative stress broadly, SS-31 specifically modulates the lipid microenvironment necessary for electron transport chain complex assembly and function.

Compound Profile

Mechanism of Action

The elamipretide mechanism centres on its selective binding to cardiolipin, a tetra-acyl phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin plays indispensable roles in mitochondrial biology: it anchors and organises electron transport chain (ETC) supercomplexes, maintains cristae curvature, facilitates cytochrome c interactions, and supports ATP synthase dimerisation.

Research by Szeto and colleagues has demonstrated that SS-31 binds to cardiolipin through electrostatic and hydrophobic interactions, stabilising the cardiolipin-cytochrome c interaction and preventing cytochrome c from converting to a peroxidase. Under normal conditions, cytochrome c shuttles electrons between Complex III and Complex IV. However, when cardiolipin becomes oxidised — as occurs during ischaemia, ageing, and metabolic disease — cytochrome c binds more tightly to damaged cardiolipin and gains peroxidase activity, further oxidising cardiolipin in a destructive positive feedback loop.

By stabilising the cardiolipin–cytochrome c electron transfer relationship, this cardiolipin peptide restores several downstream functions:

• Electron transport chain efficiency — improved supercomplex assembly reduces electron leak and ROS generation at Complexes I and III
• ATP synthesis — enhanced proton motive force coupling increases ATP output per oxygen consumed
• Cristae architecture — cardiolipin stabilisation preserves the membrane curvature necessary for efficient oxidative phosphorylation
• Mitochondrial dynamics — improved membrane integrity supports balanced fission and fusion

This mechanism is distinct from peptides like MOTS-c, which acts as a mitochondrial-derived peptide signalling molecule through AMPK activation. Whereas MOTS-c modulates cellular metabolism at the transcriptional level, SS-31 acts directly at the biophysical level of mitochondrial membrane organisation.

Barth Syndrome Research

Barth syndrome is a rare X-linked genetic disorder caused by mutations in the TAFAZZIN gene, which encodes an enzyme responsible for cardiolipin remodelling. Patients with Barth syndrome have abnormal cardiolipin species — predominantly monolysocardiolipin — leading to severe mitochondrial dysfunction, cardiomyopathy, skeletal myopathy, neutropenia, and exercise intolerance.

Because elamipretide Barth syndrome research directly targets the downstream consequences of tafazzin deficiency — specifically the disrupted cardiolipin–protein interactions — it represents a mechanistically rational therapeutic approach. Preclinical and clinical evidence supports this rationale:

• In a Phase II trial (TAZPOWER), elamipretide treatment was associated with improvements in the six-minute walk test (6MWT) distance and participant-reported measures of fatigue and muscle weakness in adolescents and adults with Barth syndrome
• A 2025 case report documented expanded-access use of elamipretide in a newborn with severe Barth syndrome-related cardiomyopathy, reporting stabilisation of cardiac function during the treatment period
• Psychometric evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) instrument from the Phase II study demonstrated that patient-reported outcomes captured meaningful changes during elamipretide treatment

Elamipretide received FDA Fast Track designation for Barth syndrome, reflecting the unmet medical need and the biological plausibility of its mechanism in this condition. However, regulatory review has been complex, and the compound has not yet received marketing approval for this indication.

Cardiac Research

Heart failure is characterised by progressive mitochondrial dysfunction, with declining cardiolipin content and composition documented in failing myocardium. SS-31 has been investigated in both preclinical models and clinical trials for heart failure with reduced ejection fraction (HFrEF).

A 2017 Phase I/II randomised, placebo-controlled trial (Daubert et al.) demonstrated that a single infusion of elamipretide produced a statistically significant reduction in left ventricular end-diastolic volume in patients with HFrEF, suggesting acute improvement in cardiac function. The peptide was well tolerated at all tested concentrations.

The larger Phase II PROGRESS-HF trial (Butler et al., 2020) evaluated 28 days of elamipretide treatment in patients with stable HFrEF. While the primary endpoint of change in left ventricular end-systolic volume did not reach statistical significance, secondary analyses showed trends toward improvement in cardiac biomarkers. The trial provided important pharmacokinetic and safety data that informed subsequent trial design.

A 2025 comprehensive review by Sabbah and colleagues integrates the cardiac research evidence and discusses how elamipretide’s mechanism — restoring cardiolipin-dependent supercomplex organisation — may explain its effects on myocardial energetics. This review contextualises SS-31 alongside other mitochondrial-targeted therapies under investigation for cardiovascular disease, including compounds that target other aspects of mitochondrial dysfunction such as BPC-157, which has been studied for its cardioprotective properties through different pathways.

Age-Related Mitochondrial Dysfunction

Mitochondrial decline is one of the hallmarks of biological ageing. With age, cardiolipin content decreases, its acyl chain composition shifts toward more saturated species, and ETC supercomplex stability deteriorates. These changes result in reduced ATP production, increased mitochondrial ROS emission, and impaired cellular quality control through mitophagy.

SS-31 has shown notable effects in preclinical models of age-related mitochondrial dysfunction:

• Skeletal muscle — Siegel et al. (2013) demonstrated that even a single treatment with this mitochondrial-targeted peptide rapidly reversed age-related declines in mitochondrial energetics and improved skeletal muscle performance in aged mice, with effects apparent within one hour
• Kidney ageing — Szeto and colleagues showed that SS-31 prevented glomerulopathy and proximal tubular injury in high-fat diet models, and protected mitochondria after acute ischaemia to prevent progression to chronic kidney disease
• Cardiac ageing — age-related cardiac hypertrophy and diastolic dysfunction were attenuated by SS-31 treatment in aged mouse models, with restoration of mitochondrial proteome homeostasis
• Tissue regeneration — a 2018 review by Szeto and Liu documented that cardiolipin-targeted peptides promoted tissue regeneration during ageing across multiple organ systems

These findings have positioned SS-31 as a compound of interest in the broader field of longevity research, alongside other peptides investigated for age-related decline such as Epithalon, which targets telomere biology through a distinct mechanism, and FOXO4-DRI, which addresses cellular senescence.

Neuroprotection Research

The brain’s high metabolic demand makes neuronal mitochondria particularly vulnerable to dysfunction. SS-31 has been investigated across several preclinical models of neurological disease and injury, with emerging evidence for neuroprotective effects:

• Spinal cord injury — a 2025 study by Ravenscraft et al. demonstrated that the mitochondrial cardiolipin-targeted tetrapeptide SS-31 exerted neuroprotective effects in both in vitro and in vivo models of spinal cord injury, reducing neuronal apoptosis and preserving mitochondrial function in injured tissue
• Diabetic retinopathy — Alam et al. (2015) showed that SS-31 reversed visual decline in mouse models of diabetes, with improvements in retinal function attributed to restored mitochondrial integrity in retinal neurons
• Glaucoma — preclinical evidence suggests mitochondria-targeted antioxidant SS-31 may offer neuroprotection for retinal ganglion cells, with potential relevance to optic neuropathies
• Neurodegenerative disease models — SS-31 has shown effects in preclinical models of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, though clinical translation in these areas remains early-stage

The neuroprotective profile of SS-31 complements other peptides under investigation for neurological applications, such as Cerebrolysin, which provides neurotrophic support through a different mechanism, and Thymosin Alpha-1, which modulates neuroinflammation through immune pathways.

Side Effects and Safety Profile

The elamipretide side effects profile has been characterised across multiple clinical trials. In general, the compound has demonstrated a favourable safety profile:

• Injection site reactions — the most commonly reported adverse event in subcutaneous administration trials, typically mild and self-limiting
• Cardiovascular monitoring — no clinically significant changes in blood pressure, heart rate, or ECG parameters were observed in Phase I and II studies
• Renal and hepatic function — laboratory parameters remained within normal limits across clinical trials
• Immunogenicity — as a small tetrapeptide, elamipretide has a low immunogenic potential, and no significant anti-drug antibody responses have been reported

Long-term safety data beyond the duration of completed clinical trials remain limited. The compound’s specificity for the mitochondrial inner membrane — rather than broad cytoplasmic activity — may contribute to its tolerability, though this hypothesis requires further validation through extended exposure studies.

All current safety information derives from controlled clinical trial settings. Researchers should note that safety profiles may differ in different populations or with prolonged use. This information is provided for research reference purposes only.

Pharmacokinetics

SS-31 exhibits several pharmacokinetic properties that distinguish it from larger peptide therapeutics:

• Absorption — rapid absorption following subcutaneous injection, with peak plasma concentrations typically reached within 30–60 minutes
• Distribution — the peptide achieves over 1,000-fold concentration within mitochondria relative to the cytoplasm, driven by its aromatic-cationic structure rather than mitochondrial membrane potential
• Metabolism — the inclusion of D-arginine and the unnatural amino acid 2′,6′-dimethyltyrosine (Dmt) confers resistance to enzymatic degradation, extending the peptide’s effective half-life compared to naturally occurring tetrapeptides
• Elimination — the plasma half-life supports once-daily subcutaneous administration in clinical trial protocols
• Cell permeability — SS-31 crosses cell membranes rapidly and in an energy-independent manner, distinguishing it from peptides that require active transport or receptor-mediated endocytosis

The compound’s small size (639.78 g/mol) places it well below the typical molecular weight threshold for cell membrane penetration. Its alternating aromatic-cationic motif — a shared structural feature across the Szeto-Schiller peptide family — appears to be the critical determinant of its membrane-penetrating behaviour.

FAQ

What is SS-31?

SS-31 is a synthetic tetrapeptide from the Szeto-Schiller peptide family that selectively targets cardiolipin in the inner mitochondrial membrane. Also known as elamipretide, it is under clinical investigation for mitochondrial diseases including Barth syndrome and heart failure. It is classified as a mitochondrial-targeted peptide and is distinct from conventional antioxidant peptides.

How does the SS-31 peptide mechanism differ from conventional antioxidants?

Conventional antioxidants work by scavenging reactive oxygen species (ROS) throughout the cell. SS-31, by contrast, concentrates specifically in the inner mitochondrial membrane where it binds to cardiolipin. This interaction stabilises electron transport chain supercomplexes, reduces electron leak at the source, and preserves mitochondrial cristae architecture — addressing the root cause of excessive mitochondrial ROS rather than neutralising ROS after they are produced.

What is the connection between elamipretide and Barth syndrome?

Barth syndrome is caused by mutations in the TAFAZZIN gene, which impairs cardiolipin remodelling. Because elamipretide directly interacts with cardiolipin to stabilise its functional interactions with mitochondrial proteins, it represents a mechanistically targeted approach to treating the downstream consequences of tafazzin deficiency. The compound has received FDA Fast Track designation for this indication.

Has SS-31 been tested in clinical trials for heart failure?

Yes. SS-31 (elamipretide) has been evaluated in multiple clinical trials for heart failure with reduced ejection fraction (HFrEF). The Phase I/II trial demonstrated acute improvements in cardiac volumes, and the Phase II PROGRESS-HF trial provided further safety and exploratory efficacy data. The compound’s mechanism of restoring mitochondrial energetics is considered relevant to heart failure pathophysiology.

What makes SS-31 a mitochondrial-targeted peptide?

SS-31’s alternating aromatic-cationic residue structure (D-Arg–Dmt–Lys–Phe–NH₂) enables it to cross cell membranes rapidly and concentrate over 1,000-fold within mitochondria. Critically, this uptake is independent of mitochondrial membrane potential — unlike TPP⁺-conjugated compounds — meaning it can still reach dysfunctional mitochondria. Once inside, it binds specifically to cardiolipin in the inner mitochondrial membrane.

What are the reported elamipretide side effects?

In clinical trials, the most commonly reported side effect has been mild injection site reactions following subcutaneous administration. No clinically significant cardiovascular, renal, or hepatic adverse effects were observed across Phase I and II studies. The compound’s small size and specificity for the mitochondrial inner membrane may contribute to its favourable tolerability profile. Long-term safety data beyond trial durations remain limited.

How does SS-31 relate to ageing research?

Mitochondrial dysfunction is a recognised hallmark of biological ageing. Preclinical studies have shown that SS-31 rapidly reverses age-related declines in mitochondrial energetics, improves skeletal muscle performance in aged mice, protects against age-related kidney and cardiac changes, and promotes tissue regeneration. These findings have made it a compound of interest in longevity research, though human ageing trials have not yet been completed.

Is SS-31 the same as elamipretide?

Yes. SS-31 is the original research designation for the compound, named as part of the Szeto-Schiller (SS) peptide series. Elamipretide is the international nonproprietary name (INN) adopted for clinical development. The compound has also been referred to as MTP-131 and Bendavia in earlier development stages. All names refer to the same D-Arg–Dmt–Lys–Phe–NH₂ tetrapeptide.

What is cardiolipin and why does it matter?

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane. It is essential for the organisation and stability of electron transport chain supercomplexes, ATP synthase function, cristae formation, and cytochrome c electron transfer. Cardiolipin dysfunction — whether from genetic mutations (as in Barth syndrome), ageing, or metabolic disease — leads to impaired energy production and increased oxidative stress. SS-31’s ability to stabilise cardiolipin interactions is the basis for its therapeutic mechanism.

Is SS-31 approved by the FDA?

As of early 2026, SS-31 (elamipretide) is not approved for any indication. It has received FDA Fast Track designation for Barth syndrome, and clinical trials are ongoing or have been completed for several conditions. The compound remains under investigation, and all current uses are limited to clinical trials or expanded-access programmes. This information is provided for research reference purposes only.

References

1. Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12(5):763-771. doi:10.1111/acel.12102. PMID: 23692570
2. Dai DF, Chiao YA, Marcinek DJ, Szeto HH, Rabinovitch PS. Mitochondrial oxidative stress in aging and healthspan. Longev Healthspan. 2014;3:6. doi:10.1186/2046-2395-3-6. PMID: 24860647
3. Alam NM, Mills WC 4th, Wong AA, Douglas RM, Szeto HH, Prusky GT. A mitochondrial therapeutic reverses visual decline in mouse models of diabetes. Dis Model Mech. 2015;8(7):701-710. doi:10.1242/dmm.020248. PMID: 26035391
4. Daubert MA, Yow E, Dunn G, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017;10(12):e004389. doi:10.1161/CIRCHEARTFAILURE.117.004389. PMID: 29217757
5. Szeto HH, Liu S. Cardiolipin-targeted peptides rejuvenate mitochondrial function, remodel mitochondria, and promote tissue regeneration during aging. Arch Biochem Biophys. 2018;660:137-148. doi:10.1016/j.abb.2018.10.013. PMID: 30359579
6. Szeto HH. Stealth Peptides Target Cellular Powerhouses to Fight Rare and Common Age-Related Diseases. Protein Pept Lett. 2018;25(12):1108-1123. doi:10.2174/0929866525666181101105209. PMID: 30381054
7. Butler J, Khan MS, Anker SD, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020;26(5):429-437. doi:10.1016/j.cardfail.2020.02.001. PMID: 32068002
8. Ortmann L, Velasco D, Cole J. Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. Eur Heart J Case Rep. 2025;9(2):ytaf030. doi:10.1093/ehjcr/ytaf030. PMID: 39917770
9. Ravenscraft B, Lee DH, Dai H, et al. Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord Injury. Int J Mol Sci. 2025;26(7):3327. doi:10.3390/ijms26073327. PMID: 40244206
10. Sabbah HN, Alder NN, Sparagna GC, et al. Contemporary insights into elamipretide’s mitochondrial mechanism of action and therapeutic effects. Biomed Pharmacother. 2025;187:118056. doi:10.1016/j.biopha.2025.118056. PMID: 40294492

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16 amino acid mitochondrial peptide with the sequence MRWQEMGYIFYPRKLR. It is encoded within the 12S rRNA gene of mitochondrial DNA — a region previously thought to contain only structural RNA components, not protein-coding sequences.[1] The discovery that mitochondria harbour short open reading frames (sORFs) capable of producing bioactive peptides fundamentally changed how researchers understand mitonuclear communication.

The MOTS-c peptide was first characterised in 2015 by Changhan David Lee’s laboratory at the University of Southern California, building on earlier work that had identified humanin as the first known mitochondrial-derived peptide.[1] While humanin was discovered through its neuroprotective effects, MOTS-c was identified through its distinct metabolic signalling properties — particularly its ability to activate AMPK and regulate cellular energy metabolism at a systemic level.

What makes MOTS-c conceptually important is that it represents a form of retrograde mitochondrial signalling. Traditionally, cellular communication flows from the nuclear genome to the mitochondria (anterograde signalling). MOTS-c demonstrates that mitochondria can signal back — producing peptide hormones that influence nuclear gene expression, metabolic pathways, and even physical performance.[3] This positions the MOTS-c peptide not as a simple metabolic intermediate, but as a genuine mitochondrial-encoded hormone.

Compound Profile

Mechanism of Action

The primary mechanism through which MOTS-c exerts its effects is activation of AMPK (AMP-activated protein kinase), the cell’s master energy sensor. AMPK activation by MOTS-c initiates a cascade of metabolic effects: increased glucose uptake, enhanced fatty acid oxidation, improved mitochondrial function, and inhibition of the folate-methionine cycle.[1] This last point is particularly notable — MOTS-c targets the folate cycle and de novo purine biosynthesis pathway, which links it to one-carbon metabolism and epigenetic regulation in ways that most metabolic peptides do not.

In the original discovery paper, Lee et al. demonstrated that MOTS-c treatment in cell culture models inhibited the folate cycle by targeting AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), leading to AMPK activation. This is mechanistically significant because AICAR is itself a well-known AMPK activator used in exercise physiology research — suggesting that MOTS-c converges on the same energy-sensing pathways activated by physical exercise.[1]

Perhaps the most striking mechanistic finding came in 2018, when Kim et al. demonstrated that MOTS-c physically translocates to the nucleus under conditions of metabolic stress.[2] Using metabolic stress conditions (glucose restriction, oxidative stress, serum deprivation), the researchers showed that MOTS-c moves from the cytoplasm into the nucleus, where it interacts with nuclear DNA and regulates the expression of genes involved in antioxidant defence and metabolic adaptation — particularly genes containing antioxidant response elements (AREs). This nuclear translocation represents a form of mitonuclear communication that had not been previously observed for any mitochondrial-derived peptide, and it fundamentally expanded the understood scope of MOTS-c’s biological activity.

The implications of nuclear translocation are profound: a peptide encoded in the mitochondrial genome can directly regulate nuclear gene expression. Benayoun and Lee (2019) described this as a “mitochondrial-encoded regulator of the nucleus,” suggesting that MOTS-c may serve as a key communication channel between the mitochondrial and nuclear genomes during periods of cellular stress.[9]

Metabolic & Insulin Sensitivity Research

The metabolic effects of MOTS-c have been studied primarily in mouse models, with results consistently demonstrating improvements in glucose homeostasis and insulin sensitivity. In the original 2015 study, intraperitoneal administration of MOTS-c to mice fed a high-fat diet prevented age-dependent and diet-induced insulin resistance, reduced obesity, and improved overall metabolic function.[1] These effects occurred even in the absence of changes in food intake, suggesting that MOTS-c influenced metabolic efficiency rather than appetite.

Cobb et al. (2016) expanded on this work by examining circulating levels of mitochondrial-derived peptides — including MOTS-c — across age groups. They found that endogenous MOTS-c levels declined with age, and that this decline correlated with age-dependent changes in insulin sensitivity and inflammatory markers.[6] This established an important connection: the natural decrease in mitochondrial peptide levels may contribute to the metabolic dysfunction that characterises ageing.

In diet-induced obesity models, MOTS-c treatment improved glucose tolerance and reduced hepatic lipid accumulation. The peptide’s effects on skeletal muscle glucose uptake are particularly relevant — MOTS-c promotes GLUT4 translocation to the cell membrane through AMPK-dependent pathways, mimicking key aspects of the insulin-sensitising effects of exercise.[7] These findings have positioned MOTS-c as a research compound of interest in the metabolic health space, alongside established compounds like semaglutide and tirzepatide — though it is critical to note that MOTS-c lacks the extensive human clinical data that supports those approved therapeutics.

Exercise Mimetic Properties

One of the most intriguing aspects of MOTS-c research is its relationship with physical exercise. Circulating MOTS-c levels increase in response to exercise in both animal models and human subjects, suggesting that the mitochondrial peptide may function as an exercise-responsive signalling molecule — effectively acting as part of the molecular machinery through which exercise produces its systemic benefits.[3]

Reynolds et al. (2021) published the most comprehensive study on this topic in Nature Communications. They demonstrated that MOTS-c levels increased in skeletal muscle following exercise, that exogenous MOTS-c administration improved physical performance in young mice, and — most notably — that MOTS-c treatment significantly improved physical capacity in aged mice.[3] The aged mice receiving MOTS-c showed improvements in running endurance, grip strength, and overall physical function that resembled the benefits of regular exercise training.

This study also showed that MOTS-c regulated the expression of genes involved in skeletal muscle homeostasis and metabolism, with effects concentrated in pathways related to myokine signalling and cellular stress resistance. The exercise connection is mechanistically consistent with MOTS-c’s known activation of AMPK — the same pathway activated by exercise and the diabetes drug metformin — placing it within a broader network of metabolic regulators that share overlapping downstream effects.

Kumagai et al. (2022) extended this work by examining the MOTS-c K14Q polymorphism (a naturally occurring variant in the MOTS-c gene) and its association with muscle fibre composition and muscular performance.[10] They found that the K14Q variant was associated with differences in muscle fibre type distribution and exercise capacity, providing genetic evidence that variations in MOTS-c sequence can influence physical performance at the population level.

It is worth noting that describing MOTS-c as an “exercise mimetic” requires qualification. While MOTS-c activates some of the same pathways as exercise, physical exercise produces a vastly broader range of systemic adaptations — cardiovascular, neurological, musculoskeletal — that no single peptide can replicate. The research suggests MOTS-c may capture specific metabolic components of the exercise response, not replace it entirely.

Longevity & Aging Research

The connection between MOTS-c and longevity has been explored through both observational genetics and experimental intervention studies. Fuku et al. (2015) examined the m.1382A>C polymorphism in the MOTS-c encoding region across Japanese populations and found that this variant was enriched in centenarians compared to younger control groups.[4] This was one of the earliest pieces of evidence suggesting that mitochondrial-derived peptide genetics may influence human lifespan.

Zempo et al. (2021) followed up with a larger study examining the K14Q polymorphism more extensively, finding that this variant — which changes a lysine to glutamine at position 14 of the MOTS-c peptide — was associated with increased risk of type 2 diabetes and metabolic dysfunction.[5] The implication is that naturally occurring variations in the MOTS-c sequence can produce measurably different metabolic outcomes, supporting the peptide’s functional significance in human metabolism.

In ageing research, the age-dependent decline in endogenous MOTS-c levels observed by Cobb et al. (2016) is consistent with the broader mitochondrial theory of ageing — the idea that declining mitochondrial function contributes to the metabolic deterioration seen with advancing age.[6] If MOTS-c levels decrease as mitochondria accumulate damage and become less functional, then the loss of this signalling molecule may represent one mechanism through which mitochondrial decline translates into systemic metabolic dysfunction.

Reynolds et al. (2021) demonstrated that MOTS-c administration reversed several markers of age-dependent physical decline in mice, including reduced exercise capacity and impaired muscle homeostasis.[3] While these results are compelling, they remain preclinical. The connection between MOTS-c and human longevity currently rests on genetic association data rather than interventional evidence, which is an important distinction for epithalon and other longevity-associated peptides as well.

MOTS-c & Mitochondrial Biology

MOTS-c’s significance extends beyond its specific metabolic effects to what it reveals about mitochondrial biology itself. The discovery that mitochondrial DNA encodes bioactive peptides — not just the 13 structural proteins and RNA components previously recognised — has opened an entirely new chapter in mitochondrial research.[8]

Mitochondrial-derived peptides (MDPs) are now understood to represent a class of retrograde signalling molecules. Where traditional models viewed mitochondria as downstream targets of nuclear gene regulation (receiving instructions from the nucleus about which proteins to produce), MDPs demonstrate that mitochondria actively signal back to the nucleus and to distant tissues through circulating peptide hormones.[9] MOTS-c’s nuclear translocation under stress conditions is the most dramatic example of this retrograde signalling — a mitochondrial-encoded peptide that physically enters the nucleus to regulate nuclear gene expression.[2]

Merry et al. (2020) reviewed the role of MDPs in energy metabolism, noting that MOTS-c and humanin appear to coordinate mitochondrial function with systemic metabolic demands — acting as molecular messengers that communicate the metabolic state of the mitochondria to the rest of the organism.[8] This positions MDPs as a potential missing link in understanding how cells and tissues coordinate their metabolic responses to stress, exercise, and ageing.

The field of MDP research remains young — MOTS-c was only discovered in 2015, and the total number of characterised mitochondrial-derived peptides remains small. However, the conceptual implications are significant: the mitochondrial genome may encode substantially more functional products than previously appreciated, and these products may play important roles in metabolic regulation, stress responses, and inter-tissue communication.

Side Effects & Safety Profile

The safety data for MOTS-c is extremely limited. As an endogenous mitochondrial peptide — meaning it is naturally produced by the body — theoretical safety concerns are less pronounced than for synthetic molecules with no endogenous counterpart. However, the absence of human clinical trial data means that no formal MOTS-c side effects profile has been established.

In preclinical mouse studies, MOTS-c administration at research doses did not produce reported adverse effects across the published literature.[1][3] Animals receiving MOTS-c showed improved metabolic markers without observable toxicity. However, preclinical safety data has well-known limitations in predicting human responses — dosing, pharmacokinetics, and immune responses can differ substantially between species.

Theoretical safety considerations for MOTS-c include:

• AMPK activation intensity — Excessive AMPK activation can theoretically suppress anabolic pathways including mTOR, which could interfere with muscle protein synthesis and other growth processes. The balance between AMPK and mTOR signalling is tightly regulated, and sustained supraphysiological AMPK activation has uncertain long-term consequences.
• Folate cycle disruption — MOTS-c inhibits the folate-methionine cycle and de novo purine synthesis.[1] While this appears to be a key mechanism underlying its metabolic effects, sustained disruption of one-carbon metabolism could theoretically impact DNA synthesis and methylation patterns.
• Immunomodulatory potential — MOTS-c’s nuclear translocation and regulation of ARE-containing genes suggests it may modulate inflammatory and immune responses.[2] The implications of exogenous MOTS-c on immune function have not been systematically evaluated.
• Unknown pharmacokinetics — The half-life, bioavailability, and tissue distribution of exogenously administered MOTS-c in humans have not been characterised.

Given these unknowns, MOTS-c remains a research compound only. No regulatory body has approved it for human use, and the absence of controlled human safety data represents a significant gap in the current evidence base.

Pharmacokinetics

The pharmacokinetic profile of MOTS-c has not been formally characterised in human studies. In preclinical research, MOTS-c has been administered primarily via intraperitoneal injection in mouse models, with demonstrated systemic bioactivity indicating that the peptide reaches target tissues and produces measurable metabolic effects.[1][3]

As a 16 amino acid peptide, MOTS-c is subject to the general pharmacokinetic limitations of peptide-based compounds: susceptibility to enzymatic degradation by circulating proteases, limited oral bioavailability, and potential rapid clearance from circulation. The half-life of exogenously administered MOTS-c has not been characterised in published literature, though endogenous MOTS-c has been detected in circulating plasma, suggesting some degree of natural stability in the bloodstream.[6]

The peptide’s ability to translocate to the nucleus after intracellular uptake indicates that MOTS-c can cross cell membranes and nuclear membranes — properties that are not universal among peptides of this size.[2] The mechanisms by which MOTS-c achieves membrane penetration and nuclear import have not been fully elucidated, though the peptide’s arginine-rich C-terminal region (PRKLR) may facilitate cellular uptake through mechanisms similar to cell-penetrating peptides.

Research into MOTS-c delivery has been limited to injectable routes in animal studies. Subcutaneous and intravenous administration routes have not been systematically compared for bioavailability or efficacy. Oral delivery would face significant challenges due to gastrointestinal peptidase degradation, consistent with the challenges facing most peptide therapeutics including compounds like sermorelin and other research peptides.

FAQ

What are the main MOTS-c benefits studied in research?

The primary MOTS-c benefits observed in preclinical research include improved insulin sensitivity, enhanced glucose homeostasis, reduced diet-induced obesity, improved physical performance in aged animals, and activation of cellular stress resistance pathways through AMPK signalling.[1][3] However, these findings come predominantly from mouse studies. Human clinical data supporting specific health benefits remains limited, and MOTS-c is not approved for any medical use.

How does MOTS-c relate to exercise?

MOTS-c levels increase in response to physical exercise in both animal models and human skeletal muscle, suggesting it functions as an exercise-responsive mitochondrial signal.[3] Exogenous MOTS-c administration has been shown to improve physical performance in aged mice, though it should not be considered a replacement for exercise — it appears to capture specific metabolic aspects of the exercise response rather than the full spectrum of exercise adaptations.

Is MOTS-c the same as humanin?

No. While both are mitochondrial-derived peptides encoded within the mitochondrial genome, MOTS-c and humanin differ in sequence, size, receptor targets, and primary biological activities. Humanin is a 24 amino acid neuroprotective peptide, while MOTS-c is a 16 amino acid metabolic signalling molecule that activates AMPK.[1] They represent different functional outputs from the mitochondrial genome.

What are the known MOTS-c side effects?

No formal MOTS-c side effects profile has been established in humans due to the absence of controlled clinical trials. In preclinical mouse studies, no adverse effects were reported at research doses.[1][3] Theoretical concerns include potential disruption of folate-methionine metabolism and the consequences of sustained AMPK activation, but these remain speculative without human data.

Does MOTS-c have anti-aging properties?

Preclinical evidence suggests potential relevance to ageing research: MOTS-c levels decline with age, genetic variants in the MOTS-c sequence are associated with exceptional longevity in Japanese populations, and MOTS-c administration reversed age-dependent physical decline in mice.[3][4][6] However, describing MOTS-c as an “anti-aging” compound overstates the current evidence, which remains preliminary and has not been validated in human longevity studies.

How is MOTS-c administered in research?

In published preclinical studies, MOTS-c has been administered primarily via intraperitoneal injection in mouse models.[1][3] The pharmacokinetics, optimal delivery route, and dosing parameters for any potential human application have not been established. As a peptide compound, oral bioavailability would be expected to be very low.

What is the MOTS-c K14Q polymorphism?

The K14Q polymorphism (m.1382A>C) is a naturally occurring genetic variant in the MOTS-c coding region that changes a lysine to glutamine at position 14 of the peptide. This variant has been associated with increased type 2 diabetes risk and differences in muscle fibre composition and exercise performance.[5][10] It represents one of the first demonstrations that naturally occurring variations in a mitochondrial-derived peptide sequence can influence metabolic outcomes at the population level.

What is the evidence confidence level for MOTS-c?

The evidence confidence for MOTS-c is best described as Limited-Moderate. The mechanistic data is strong — AMPK activation, nuclear translocation, and metabolic effects are well-documented in cell and animal models across multiple research groups.[1][2][3] However, human clinical trial data is essentially absent, and long-term safety data does not exist. This places MOTS-c in the early stages of translational research, with promising preclinical findings that await clinical validation.

References

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed
2. Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. PubMed
3. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed
4. Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015;14(6):921-923. PubMed
5. Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. PubMed
6. Cobb LJ, Lee C, Xiao J, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY). 2016;8(4):796-809. PubMed
7. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016;100:182-187. PubMed
8. Merry TL, Chan A, Woodhead JST, et al. Mitochondrial-derived peptides in energy metabolism. Am J Physiol Endocrinol Metab. 2020;319(4):E659-E666. PubMed
9. Benayoun BA, Lee C. MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus. BioEssays. 2019;41(9):e1900046. PubMed
10. Kumagai H, Natsume T, Kim SJ, et al. The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance. Biochim Biophys Acta Gen Subj. 2022;1866(2):130048. PubMed